Skip to main content
. 2017 Jan 19;2017(1):CD012040. doi: 10.1002/14651858.CD012040.pub2

1.3. Analysis.

Comparison 1 Ataluren versus placebo, Outcome 3 FEV₁ ‐ mean relative change from baseline: subgroup analysis of participants receiving chronic inhaled tobramycin.